Legend Biotech: CARVYKTI® Q4 Preliminary Sales Hit $159M
Ticker: LEGN · Form: 6-K · Filed: Jan 23, 2024 · CIK: 1801198
| Field | Detail |
|---|---|
| Company | Legend Biotech Corp (LEGN) |
| Form Type | 6-K |
| Filed Date | Jan 23, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $159 million |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: preliminary-sales, drug-sales, collaboration-agreement, pharmaceuticals
TL;DR
**Legend Biotech's CARVYKTI® just posted preliminary Q4 sales of $159M, watch for final numbers.**
AI Summary
Legend Biotech Corp. announced on January 23, 2024, that its multiple myeloma drug, CARVYKTI®, generated approximately $159 million in preliminary net trade sales for the quarter ended December 31, 2023. This figure, provided by collaboration partner Janssen Biotech, Inc., is subject to Legend Biotech's final financial statement completion. This matters to investors because CARVYKTI® is a key product, and strong sales indicate potential for increased revenue and profitability, though the preliminary nature means the final numbers could differ.
Why It Matters
This filing provides an early look at the sales performance of CARVYKTI®, a critical drug for Legend Biotech, giving investors insight into potential revenue for the last quarter of 2023.
Risk Assessment
Risk Level: medium — The sales figure is preliminary and unverified by Legend Biotech, meaning the final reported amount could change, introducing some uncertainty.
Analyst Insight
A smart investor would note the preliminary nature of the $159 million sales figure for CARVYKTI® and await Legend Biotech's final audited financial statements for the quarter ended December 31, 2023, before making investment decisions based solely on this number.
Key Numbers
- $159 million — Preliminary Net Trade Sales of CARVYKTI® (Represents the estimated revenue generated by their key drug for Q4 2023.)
- December 31, 2023 — Quarter End Date (Specifies the period to which the sales figures apply.)
Key Players & Entities
- Legend Biotech Corporation (company) — the registrant and announcer of sales figures
- Janssen Biotech, Inc. (company) — collaboration partner providing sales information
- CARVYKTI® (product) — the drug whose sales are being reported
- $159 million (dollar_amount) — preliminary net trade sales for CARVYKTI®
- December 31, 2023 (date) — end of the quarter for which sales are reported
- January 23, 2024 (date) — date of the report and announcement
Forward-Looking Statements
- Legend Biotech's final reported revenue for Q4 2023 will be close to the preliminary $159 million for CARVYKTI®. (Legend Biotech Corporation) — medium confidence, target: Q1 2024 (when Q4 2023 financials are released)
- Janssen Biotech, Inc. will continue to be a key partner in reporting CARVYKTI® sales. (Janssen Biotech, Inc.) — high confidence, target: Ongoing
FAQ
What is the specific drug mentioned in this 6-K filing?
The specific drug mentioned in this 6-K filing is CARVYKTI®.
What was the preliminary net trade sales figure for CARVYKTI® for the quarter ended December 31, 2023?
CARVYKTI® generated approximately $159 million in preliminary net trade sales for the quarter ended December 31, 2023.
Which company provided the sales information to Legend Biotech Corporation?
Janssen Biotech, Inc. provided the sales information to Legend Biotech Corporation, pursuant to their Collaboration and License Agreement dated December 21, 2017.
Has Legend Biotech Corporation independently verified the accuracy of the reported sales figure?
No, Legend Biotech Corporation has not independently verified the accuracy of the sales figure, as stated in the filing.
What is the significance of the sales figure being 'preliminary'?
The sales figure is preliminary because it is subject to completion by Legend Biotech's management of their financial statements for the period ended December 31, 2023, and has not been audited by their independent registered public accountants.
Filing Stats: 782 words · 3 min read · ~3 pages · Grade level 19 · Accepted 2024-01-23 07:30:13
Key Financial Figures
- $159 million — d that CARVYKTI generated approximately $159 million in net trade sales during the quarter e
Filing Documents
- a53886644.htm (6-K) — 15KB
- 0001157523-24-000091.txt ( ) — 16KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. LEGEND BIOTECH CORPORATION Date: January 23, 2024 By: /s/ Ying Huang Name: Ying Huang, Ph.D. Title: Chief Executive Officer